Page 4 - Johnc Klock News Today

SG Americas Securities LLC boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 632.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,545 shares of the biotechnology company’s stock after purchasing an additional 10,832 shares […]

Nisa Investment Advisors LLC trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 16.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,361 shares of the biotechnology company’s stock after selling 3,830 shares during the period. Nisa […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) had its price objective increased by research analysts at Robert W. Baird from $112.00 to $127.00 in a report released on Thursday, The Fly reports. Robert W. Baird’s price target points to a potential upside of 36.56% from the company’s current price. Other equities research analysts have also recently […]

Mesirow Institutional Investment Management Inc. increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 5.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,980 shares of the biotechnology company’s stock after acquiring an additional 1,200 shares during the quarter. Mesirow […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) issued an update on its FY23 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $1.80-2.05 for the period, compared to the consensus estimate of $1.98. The company issued revenue guidance of $2.375-2.500 billion, compared to the consensus revenue estimate of $2.46 billion. BioMarin […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Rating) is set to issue its quarterly earnings data after the market closes on Wednesday, April 26th. Analysts expect the company to announce earnings of $0.43 per share for the quarter. BioMarin Pharmaceutical has set its FY 2023 guidance at $1.80-$2.05 EPS.Individual that wish to register for the company’s earnings […]

Emerald Advisers LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 8,845 shares of the biotechnology company’s stock, valued at approximately $915,000. Other hedge funds and other institutional investors have also recently bought […]

DekaBank Deutsche Girozentrale boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 2.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 296,567 shares of the biotechnology company’s stock after buying an additional 7,280 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in BioMarin Pharmaceutical were worth $30,273,000 as of its […]

Redwood Wealth Management Group LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,172 shares of the biotechnology company’s stock, valued at approximately $328,000. Other hedge funds also […]

Dupont Capital Management Corp lowered its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Rating) by 83.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 517 shares of the biotechnology company’s stock after selling 2,649 shares during the quarter. Dupont Capital Management Corp’s […]